Lay-Skilling trial no lay up for the Enron Task Force

skilling and lay6.jpgProfessors Bainbridge and Ribstein point to this Roger Parloff/Fortune magazine article that does a good job of summarizing the problems that confront the Enron Task Force in making its case against former key Enron executives Ken Lay and Jeff Skilling, a point that has been addressed in recent posts here, here, here and here. Professor Ribstein places the particular problems with the Task Force’s case against Lay and Skilling in the larger context of how justice and respect for the rule of law is eroded by such criminalization of corporate agency costs:

Lay and Skilling were not the best managers money could buy. But to apportion guilt in a way that maximizes the law’s deterrence function requires a scalpel, not the bludgeon of the criminal law.
And the moral force of the criminal law should be reserved for the cases that deserve it. Even if Lay and Skilling are convicted, the question wonít turn on, for example, whether they were at the scene of the crime. Of course they were. But the jury has to make a very difficult determination as to the precise positions of their eyes and ears. Years in jail should not hang on such details.

Just as years in jail should not hang on one’s duty to handle the closing of a presumably legal deal or one’s obtaining of an unenforceable oral assurance related to such a deal.
Peter Elkind and Bethany McLean, authors of the Enron book The Smartest Guys in the Room (Portfolio 2003), also weigh in here with a more extensive background piece on the case, which includes numerous examples of their decidedly biased view toward the Lay-Skilling defense. The piece is another example of the conflict of interest in covering the Lay-Skilling case that is common among certain mainstream media sources who have a vested interest in presenting the case in a light that is consistent with the view embraced in their book (that point was addressed earlier here).

A lot about Alito

Alito4.jpgMost of us don’t have time to watch much of the Senate Judiciary Committee hearing on President Bush’s nomination of Samuel A. Alito, Jr. to the U.S. Supreme Court, so here are a few items to help you catch up on the festitivities.
A Washington Post video of the tasty and testy exchange between Senators Kennedy and Spector over Kennedy’s request to subpoena some documents.
Peggy Noonan’s analysis of the hearing to date, including this recitation (fictional, I hope) of the typical quality of Senator Joe Biden’s questioning (?) of Judge Alito:

What if a fella–I’m just hypothesizing here, Judge Alito–what if a fella said, “Well I don’t want to hire you because I don’t like the kind of eyeglasses you wear,” or something like that. Follow my thinking here. Or what if he says “I won’t hire you because I don’t like it that you wear black silk stockings and a garter belt. And your name is Fred.” Strike that–just joking, trying to lighten this thing up, we can all be too serious. Every 10 years when you see me at one of these hearings I am different from every other member of Judiciary in that I have more hair than the last time. You know why? It’s all the activity in my brain! It breaks through my skull and nourishes my follicles with exciting nutrients! Try to follow me.

Noonan wonders: “How does Judge Alito put up with this?”
Meanwhile, a measured criticism of Judge Alito’s nomination is contained in this Jonathon Turley/USA Today op-ed in which Turley observes as follows:

Despite my agreement with Alito on many issues, I believe that he would be a dangerous addition to the court in already dangerous times for our constitutional system. Alito’s cases reveal an almost reflexive vote in favor of government, a preference based not on some overriding principle but an overriding party.
In my years as an academic and a litigator, I have rarely seen the equal of Alito’s bias in favor of the government. To put it bluntly, when it comes to reviewing government abuse, Samuel Alito is an empty robe.
Alito’s writings and opinions show a jurist who is willing to yield tremendous authority to the government and offer little in terms of judicial review — views repeatedly rejected not only by his appellate colleagues but also by the U.S. Supreme Court.
An independent judiciary means little if our judges are not independently minded. In criminal, immigration and other cases, Alito is one of the government’s most predictable votes on the federal bench. Though his supporters have attempted to portray this as merely a principle of judicial deference, it is a raw form of judicial bias.

Read the entire piece.
Finally, don’t miss the Comedy Central video “Sam’s Club,” particularly the final 1.5 minutes where the current hearing is compared to another senate committee hearing that is familiar to all movie buffs.

The Stros connection to the latest Hall of Fame inductee

bruce_sutter.jpgFormer MLB relief pitcher Bruce Sutter was voted into Baseball’s Hall of Fame earlier this week, although he probably should not have been. The fact that Sutter won MLB’s National League Cy Young Award (awarded annually to the league’s best pitcher) in 1979 may well tipped the scales in favor of Sutter’s Hall-of-Fame candidacy in some voters’ eyes. But a little known fact is that Sutter did not deserve that Cy Young Award, either, and that voter ignorance in evaluating the value of two former Stros pitchers figured prominently in Sutter winning award that season.
Sutter won the 1979 NL Cy Young Award by taking 77 of a possible 120 points, but he garnered only 10 of the 24 first-place votes. Sutter benefited from an absurd split vote that developed over Stros teammates, Joe Niekro and J.R. Richard, who shared 13 of the other 14 first-place votes.
Despite that split vote, Richard was the superior pitcher that season, particularly over Niekro. Richard pitched far more innings (292.1) than either Niekro (263.2) or Sutter (101.1), and had a more impressive 313/98 strikeout-to-walk ratio as compared with Niekroís 119/107 and Sutter’s 110/32. Moreover, Richard saved 19 more runs for his team than an average National League pitcher would have that season (“RSAA,” explained here) while Niekro had an 8 RSAA and eight fewer complete games than Richard.
So, why was Niekro even in the competition for the Cy Young Award that season with Sutter and Richard? In essence, because he was luckier than Richard. Niekro had a 21-11 won/loss record that season versus Richardís 18-13, a misleading statistic that ended up generating Niekro nine first-place votes to Richardís four. Thus, Sutterís Cy Young Award that season — and quite possibly his Hall of Fame induction this year — is largely attributable to the ignorance of a substantial number of voters in evaluating the performance of these three pitchers during the 1979 season. Under any reasonable interpretation of performance, Richard wins the 1979 NL Cy Young Award easily and a major part of the justification for Sutterís Hall of Fame candidacy — particularly over superior pitchers such as Goose Gossage and Bert Blylevyn — goes by the wayside.
By the way, Richard followed up that great 1979 season with an even better one midway through the 1980 season (20 RSAA, 1.90 ERA and 119/40 strikeout to walk ratio in 113.2 innings) when he was struck down by a tragic stroke that effectively ended his ability to play baseball in the prime of his career (Richard was 30 years old at the time).

J&J ups the ante for Guidant

guidant_logo_web6.jpgJust when you think Johnson & Johnson might pick up its chips, accept its $625 million breakup fee and go home from the poker game with Boston Scientific Corp. over Guidant Corp., J&J sweetened the pot with a $23.2 billion bid for the Indianapolis-based, heart device maker. Earlier posts on the competition for Guidant can be reviewed here.
J&J’s new bid, which both J&J and Guidant boards have accepted, increased its value to $68.06 for each Guidant share from the $64 per share value of its previous offer. Boston Scientific’s jilted offer was for about $25 billion (or $72 a share), but is not as certain to close and does not have the liquidity features of the J&J bid. The market responded to the news of a possible all-out bidding war by increasing the value of Guidant’s shares over $1 to $70.44 on the New York Stock Exchange.
It’s an incredible turnaround for Guidant. After making a $25.4 billion ($76 per share) offer in December 2004, J&J started crawfishing on the deal last year by lowering its bid to below $22 billion ($63 a share) when Guidant’s market share dropped from about 35 percent to 25 percent amidst reports of patient deaths caused by allegedly defective products. That development induced Boston Scientific to jump into the fray with its competing $25 billion bid and — presto! — Guidant had gone in a matter of days from being worked over the coals by one buyer to being the darling of two.
Although much smaller and more highly-leveraged than J&J, Boston Scientific announced in response to J&J’s increased bid that it is studying whether to increase its competing bid for Guidant. Boston Scientific’s shares have decreased in value more than 40% from their peak value in 2004 as the company continues to rely heavily on sales of its primary product, the Taxus Express cardiac stent. Thus, Boston Scientific continues to have incentive to pursue the acquisition of Guidant, which would diversify Boston Scientific’s product line and provide the basis for greater growth potential. Stay tuned.